Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) EBT Margin (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed EBT Margin for 12 consecutive years, with 546.74% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT Margin rose 45067.0% year-over-year to 546.74%, compared with a TTM value of 769.39% through Dec 2025, down 272329.0%, and an annual FY2025 reading of 765.89%, down 273304.0% over the prior year.
  • EBT Margin was 546.74% for Q4 2025 at Agios Pharmaceuticals, up from 803.05% in the prior quarter.
  • Across five years, EBT Margin topped out at 11167.28% in Q3 2024 and bottomed at 12073.44% in Q1 2022.
  • Average EBT Margin over 4 years is 1190.46%, with a median of 1184.15% recorded in 2023.
  • The sharpest move saw EBT Margin soared 1240156bps in 2024, then plummeted -1197033bps in 2025.
  • Year by year, EBT Margin stood at 2150.44% in 2022, then skyrocketed by 36bps to 1374.81% in 2023, then increased by 27bps to 997.41% in 2024, then surged by 45bps to 546.74% in 2025.
  • Business Quant data shows EBT Margin for AGIO at 546.74% in Q4 2025, 803.05% in Q3 2025, and 903.6% in Q2 2025.